Ironwood Pharmaceuticals (IRWD) to Release Earnings on Monday

Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to be releasing its earnings data after the market closes on Monday, February 19th. Analysts expect Ironwood Pharmaceuticals to post earnings of ($0.18) per share for the quarter.

Shares of Ironwood Pharmaceuticals (IRWD) opened at $13.73 on Monday. The company has a current ratio of 4.87, a quick ratio of 4.86 and a debt-to-equity ratio of -22.31. Ironwood Pharmaceuticals has a 52-week low of $12.89 and a 52-week high of $19.94. The company has a market capitalization of $2,056.14, a PE ratio of -14.15 and a beta of 1.29.

In related news, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $15.12, for a total value of $1,714,683.60. Following the transaction, the chief executive officer now owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark G. Currie sold 60,000 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $15.45, for a total value of $927,000.00. Following the completion of the sale, the insider now directly owns 835,000 shares in the company, valued at approximately $12,900,750. The disclosure for this sale can be found here. Insiders sold a total of 174,905 shares of company stock worth $2,666,359 in the last 90 days. 7.63% of the stock is currently owned by insiders.

A number of research firms have recently commented on IRWD. Morgan Stanley reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 4th. ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. Mizuho cut Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $20.00 to $16.00 in a research report on Wednesday, December 6th. Credit Suisse Group assumed coverage on Ironwood Pharmaceuticals in a research report on Monday, November 27th. They issued a “buy” rating and a $19.00 price target on the stock. Finally, Bank of America cut Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and dropped their price target for the company from $20.00 to $15.00 in a research report on Friday, January 5th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $17.56.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/12/ironwood-pharmaceuticals-irwd-to-release-earnings-on-monday.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply